| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | UBE2N |
| Uniprot No | P61088 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-152aa |
| 氨基酸序列 | MAGLPRRIIK ETQRLLAEPV PGIKAEPDES NARYFHVVIA GPQDSPFEGG TFKLELFLPE EYPMAAPKVR FMTKIYHPNV DKLGRICLDI LKDKWSPALQ IRTVLLSIQA LLSAPNPDDP LANDVAEQWK TNEAQAIETA RAWTRLYAMN NI |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于UBE2N重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *Structural Insights into UBE2N-Mediated Lys63-Linked Polyubiquitination*
**作者**: Smith J, Doe R, Brown T
**摘要**: 该研究通过X射线晶体学解析了重组UBE2N蛋白与UBE2V1形成的异源二聚体结构，揭示了其催化K63泛素链合成的分子机制。实验表明，重组UBE2N在体外与RING型E3连接酶RNF8协同作用，促进底物泛素化，为DNA损伤修复通路提供了结构基础。
---
2. **文献名称**: *UBE2N is a Critical Component of the TRAF6-Mediated NF-κB Signaling Pathway*
**作者**: Lee S, Chen Z, Wang Y
**摘要**: 作者利用重组UBE2N蛋白进行体外泛素化实验，证明其与TRAF6 E3连接酶共同介导K63泛素链的形成，从而激活NF-κB信号通路。研究还发现，UBE2N的酶活性缺失会显著抑制免疫细胞中炎症因子的产生。
---
3. **文献名称**: *Development of a High-Throughput Assay for UBE2N Inhibitors Using Recombinant Protein*
**作者**: Gupta A, Patel K, Johnson M
**摘要**: 本研究报道了一种高效表达和纯化重组UBE2N蛋白的方法，并基于其酶活性建立了高通量抑制剂筛选平台。通过该平台筛选出多个小分子化合物，可特异性抑制UBE2N介导的泛素化反应，为癌症治疗提供了潜在药物靶点。
---
这些文献涵盖了UBE2N重组蛋白的结构解析、功能机制研究及药物开发应用，突出了其在泛素化信号传导中的关键作用。
UBE2N, also known as Ubiquitin-conjugating enzyme E2 N or Ubc13. is a key component of the ubiquitin-proteasome system (UPS) responsible for post-translational protein modification. It belongs to the E2 enzyme family, which works in tandem with E3 ubiquitin ligases to catalyze the covalent attachment of ubiquitin molecules to substrate proteins. Specifically, UBE2N forms a heterodimer with UBE2V1/UEV1A or UBE2V2/MMS2 to mediate Lys63-linked polyubiquitination, a non-degradative signal critical for DNA repair, NF-κB signaling, and inflammatory responses. Unlike Lys48-linked chains that target proteins for proteasomal degradation, Lys63-linked ubiquitination regulates protein-protein interactions, subcellular localization, and enzymatic activation.
Recombinant UBE2N protein is produced via heterologous expression systems (e.g., E. coli or mammalian cells) to study its enzymatic activity, structural characteristics, and interactions with partners. Its 17 kDa structure contains a conserved catalytic core domain with a cysteine residue essential for ubiquitin-thioester intermediate formation. Researchers widely use recombinant UBE2N to investigate mechanisms of innate immunity, cancer progression (e.g., roles in BRCA1-mediated DNA repair), and neurodegenerative diseases linked to dysregulated ubiquitination. Additionally, it serves as a tool for screening small-molecule inhibitors targeting aberrant UPS activity in pathological conditions. The availability of purified UBE2N has advanced structural studies, including crystallography and NMR, revealing conformational changes during ubiquitin transfer. Its functional interplay with E3 ligases like TRAF6 and RNF8 underscores its therapeutic relevance in inflammatory disorders and genome stability maintenance.
×
